INT210061

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.20
First Reported 2007
Last Reported 2008
Negated 3
Speculated 0
Reported most in Body
Documents 6
Total Number 8
Disease Relevance 1.81
Pain Relevance 0.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (SH3GL3) endosome (SH3GL3) signal transduction (SH3GL3)
cytoplasm (SH3GL3)
Anatomy Link Frequency
body 3
plasma 2
urine 2
SH3GL3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 54 100.00 Very High Very High Very High
aspirin 6 86.72 High High
Antihistamine 2 79.60 Quite High
corticosteroid 2 78.16 Quite High
Central nervous system 17 76.56 Quite High
imagery 18 67.96 Quite High
Paracetamol 4 44.48 Quite Low
cva 24 35.40 Quite Low
Pain score 20 26.40 Quite Low
fibrosis 18 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pain 74 100.00 Very High Very High Very High
Hypersensitivity 2 90.72 High High
Cv General 4 Under Development 3 90.64 High High
Fabry Disease 216 89.60 High High
Renal Disease 150 87.24 High High
Disease 148 85.64 High High
Proteinuria 270 83.04 Quite High
Congenital Anomalies 8 68.52 Quite High
Coronary Heart Disease 41 68.44 Quite High
Left Ventricular Hypertrophy 22 57.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Despite decreased plasma and urine GL-3 levels, there were no significant changes in urinary protein excretion and serum creatinine levels.
Neg (no) Regulation (changes) of urine GL-3 in urine
1) Confidence 0.20 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.24 Pain Relevance 0.11
D) Do short-term changes in urinary GL-3 excretion reflect changes in the total body GL-3 load, or just changes in renal GL-3?
Regulation (changes) of GL-3 in body
2) Confidence 0.11 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.20 Pain Relevance 0.04
D) Do short-term changes in urinary GL-3 excretion reflect changes in the total body GL-3 load, or just changes in renal GL-3?
Regulation (changes) of GL-3 in body
3) Confidence 0.11 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.19 Pain Relevance 0.04
D) Do short-term changes in urinary GL-3 excretion reflect changes in the total body GL-3 load, or just changes in renal GL-3?
Regulation (body) of GL-3 in body
4) Confidence 0.11 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.19 Pain Relevance 0.04
Despite decreased plasma and urine GL-3 levels, there were no significant changes in urinary protein excretion and serum creatinine levels.
Neg (no) Regulation (changes) of urine GL-3 in plasma
5) Confidence 0.07 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.24 Pain Relevance 0.11
In line with the similarity in clinical responses to agalsidase alfa and beta treatments at 0.2 mg/kg biweekly, the reductions in plasma and urinary GL-3 in both treatment groups were not significantly different.
Neg (not) Regulation (different) of GL-3 in plasma
6) Confidence 0.03 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1913555 Disease Relevance 0.22 Pain Relevance 0
Further exploratory analysis was performed on the relation between GL-3 levels and treatment failure.
Regulation (relation) of GL-3
7) Confidence 0.03 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1913555 Disease Relevance 0.25 Pain Relevance 0.03
The objective of the current study was to compare the efficacy of agalsidase alfa and beta at an equal dose of 0.2 mg/kg given once every two weeks, in Fabry patients with respect to 1. decrease in cardiac mass 2. changes in GFR, pain and GL-3 in serum and urine 3. number of treatment failures.


Regulation (changes) of GL-3 in urine associated with pain
8) Confidence 0.02 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1913555 Disease Relevance 0.27 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox